

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEGS1646

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	MAR 15	WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS	3	MAR 16	CASREACT coverage extended
NEWS	4	MAR 20	MARPAT now updated daily
NEWS	5	MAR 22	LWPI reloaded
NEWS	6	MAR 30	RDISCLOSURE reloaded with enhancements
NEWS	7	APR 02	JICST-EPLUS removed from database clusters and STN
NEWS	8	APR 30	GENBANK reloaded and enhanced with Genome Project ID field
NEWS	9	APR 30	CHEMCATS enhanced with 1.2 million new records
NEWS	10	APR 30	CA/CAPplus enhanced with 1870-1889 U.S. patent records
NEWS	11	APR 30	INPADOC replaced by INPADOCDB on STN
NEWS	12	MAY 01	New CAS web site launched
NEWS	13	MAY 08	CA/CAPplus Indian patent publication number format defined
NEWS	14	MAY 14	RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS	15	MAY 21	BIOSIS reloaded and enhanced with archival data
NEWS	16	MAY 21	TOXCENTER enhanced with BIOSIS reload
NEWS	17	MAY 21	CA/CAPplus enhanced with additional kind codes for German patents
NEWS	18	MAY 22	CA/CAPplus enhanced with IPC reclassification in Japanese patents
NEWS	19	JUN 27	CA/CAPplus enhanced with pre-1967 CAS Registry Numbers
NEWS	20	JUN 29	STN Viewer now available
NEWS	21	JUN 29	STN Express, Version 8.2, now available
NEWS	22	JUL 02	LEMBASE coverage updated
NEWS	23	JUL 02	LMEDLINE coverage updated
NEWS	24	JUL 02	SCISEARCH enhanced with complete author names
NEWS	25	JUL 02	CHEMCATS accession numbers revised
NEWS	26	JUL 02	CA/CAPplus enhanced with utility model patents from China
NEWS	27	JUL 16	CAplus enhanced with French and German abstracts
NEWS	28	JUL 18	CA/CAPplus patent coverage enhanced
NEWS EXPRESS	29	JUNE 2007:	CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation

of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 10:49:12 ON 18 JUL 2007

=> File .gerry2MBCE
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'MEDLINE' ENTERED AT 10:49:38 ON 18 JUL 2007

FILE 'BIOSIS' ENTERED AT 10:49:38 ON 18 JUL 2007

Copyright (c) 2007 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 10:49:38 ON 18 JUL 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 10:49:38 ON 18 JUL 2007

Copyright (c) 2007 Elsevier B.V. All rights reserved.

=> S G-CSF (L) (Treatm? OR Therapy) (5A) (renal(2A) ((disease OR Failure) OR Nephropathy)) AND pd<=20041014

1 FILES SEARCHED...

2 FILES SEARCHED...

L1 6 G-CSF (L) (TREATM? OR THERAPY) (5A) (RENAL(2A) ((DISEASE OR FAILURE) OR NEPHROPATHY)) AND PD<=20041014

=> Dup Rem l1

PROCESSING COMPLETED FOR L1

L2 4 DUP REM L1 (2 DUPLICATES REMOVED)

ANSWER '1' FROM FILE MEDLINE

ANSWER '2' FROM FILE BIOSIS

ANSWER '3' FROM FILE CAPLUS

ANSWER '4' FROM FILE EMBASE

=> D IBib ABS l2 1-4

L2 ANSWER 1 OF 4 MEDLINE on STN DUPLICATE 1

ACCESSION NUMBER: 2000388203 MEDLINE

DOCUMENT NUMBER: PubMed ID: 10914557

TITLE: Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure.

AUTHOR: Tosi P; Zamagni E; Ronconi S; Benni M; Motta M R; Rizzi S; Tura S; Cavo M

CORPORATE SOURCE: Institute of Hematology and Medical Oncology, Seragnoli University of Bologna, Italy.

SOURCE: Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, (2000 Jul) Vol. 14, No. 7, pp. 1310-3. Journal code: 8704895. ISSN: 0887-6924.

PUB. COUNTRY: ENGLAND: United Kingdom

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE) (RESEARCH SUPPORT, NON-U.S. GOV'T)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200008

ENTRY DATE: Entered STN: 18 Aug 2000
Last Updated on STN: 18 Aug 2000
Entered Medline: 10 Aug 2000

AB Patients with multiple myeloma (MM) and chronic renal failure have generally been excluded from myeloablative therapy programs followed by hematopoietic stem cell support because of the potential increase in transplant-related morbidity and mortality. We here report our experience treating six MM patients with moderate to severe renal insufficiency, with autologous stem cell transplantation. One of these patients required chronic hemodialysis since the diagnosis of MM was made. Peripheral blood stem cell collection was performed with either cyclophosphamide 5.5-7 g/m² + G-CSF, 5 microg/kg/day (patients 1-3, 5 and 6) or G-CSF, 15 microg/kg/day alone (patient Number 4). Four patients (Nos 1-4) received autotransplant as front-line therapy, while the last two patients were treated in relapse, which occurred following prior autologous stem cell transplantation in support of melphalan, 200 mg/m² (Number 5) or maintenance therapy with alpha-interferon (Number 6). High-dose chemotherapy administered as preparation to transplant included busulfan 12 mg/kg + melphalan 80 mg/m² (patients 1-3 and 6) or melphalan 80 mg/m² alone (patients 4 and 5) in order to reduce mucosal damage. Following transplant, prompt and sustained recovery of hematopoiesis was documented in all the patients; 500 PMN/microI and 20000 platelets/microI were reached after a median of 13 and 14 days, respectively. None of the patients suffered from WHO grade 3-4 infectious complications. Transplant-related toxicity included grade 3-4 oral mucositis (patients 1, 4 and 5) and veno-occlusive disease (patient Number 3). Renal function either improved or remained stable throughout the transplant period. All the patients but one responded to therapy, three of them are progression free after 2, 15 and 26 months; two relapsed after 16 and 4 months and one died from cholangiocarcinoma 7 months after transplant, while still in remission. Although our experience is limited so far, these results appear promising and support the investigational use of myeloablative therapy in MM patients with chronic renal failure.

L2 ANSWER 2 OF 4 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
ACCESSION NUMBER: 2002:186929 BIOSIS
DOCUMENT NUMBER: PREV200200186929
TITLE: The Royal Marsden Hospital leukemia-myeloma database: An "operations research" resource for assessing clinical outcomes and planning new drug trials.
AUTHOR(S): Powles, Ray [Reprint author]; Milan, Sarah [Reprint author]; Horton, Clive [Reprint author]; Sirohi, Bhawna [Reprint author]; Treleaven, Jennie [Reprint author]; Singhal, Seema [Reprint author]; Mehta, Jayesh [Reprint author]
CORPORATE SOURCE: Royal Marsden Hospital, Surrey, UK
SOURCE: Blood, (November 16, 2001) Vol. 98, No. 11 Part 1, pp. 426a. print.
Meeting Info.: 43rd Annual Meeting of the American Society of Hematology, Part 1. Orlando, Florida, USA. December 07-11, 2001. American Society of Hematology.
CODEN: BLOOAW. ISSN: 0006-4971.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
Conference; (Meeting Poster)
LANGUAGE: English
ENTRY DATE: Entered STN: 13 Mar 2002
Last Updated on STN: 13 Mar 2002

AB Operations research is the application of scientific methods to solve complex organizational problems including improving existing systems and designing new systems well. It is widely used in industry, finance, and

education. We have been using operations research to manage leukemia and myeloma patients for over 2 decades. Since 1978, comprehensive data have been collected prospectively on 3500+ consecutive unselected population-based patients referred to the RMH Leukaemia and Myeloma Units. For each patient, up to 600 separate data fields are recorded with multiple, longitudinal prospective values for each (e.g. serial blood counts recorded on all the days they are done - a "sparse array") on all aspects of disease and therapy. The database comprises a definition, collection and query/analysis package written in MUMPS, and presently contains approx 2X10⁷ data items. The purpose behind its depth and breadth is to use the information for optimal clinical decision-making, outcomes analysis and planning studies on a regular basis - which also assures its quality and accuracy in an on-going fashion (Koerner 1964, Hiller-Lieberman 1974). It is possible to obtain information on a defined patient population at any instant in time (snapshot) or over a given period (panorama). For e.g., some of the information provided by a myeloma snapshot is: (a) number of living patients, (b) number in CR or PR, (c) number on maintenance interferon therapy, (d) number on induction/reinduction, (e) number with renal failure, (f) number on erythropoietin or G-CSF, etc. Some of the information provided by a myeloma panorama for the last year is: (a) number of new/relapsed patients seen, (b) number not responding to initial therapy, (c) number of patients relapsing after the first autograft, (d) number of patients failing post-autograft salvage therapy, (e) number presenting with renal failure, (f) number autografted, etc. For each group identified, detailed clinical, hematologic/biochemical data are available. Extrapolating this to the future, with specific inclusion/exclusion criteria, it is possible to predict accurately how many patients can be recruited for a study over a period of time. Thus, for a proposed 1-year study of a new drug in myeloma patients relapsing after the first autograft with normal renal function, 83 patients can be enrolled almost immediately (the number alive today with disease relapsing after first autograft) and 21 more over the next year (based upon the number relapsing over last year). By changing the inclusion to any relapse, the total number increases to 112, and by eliminating the renal function criterion, to 114. Similar analyses can also be done for leukemia. The strength of this analysis is that it can be extrapolated to other centers. It is becoming increasingly difficult to test drugs in modern health care environment due to appropriately stringent demands from drug regulatory bodies and organizations overseeing the interests of research subjects. Delays in completing pivotal trials can place large financial burdens on pharmaceutical companies which can partly be avoided by projecting enrollment based on such databases. Multi-institutional databases have larger patient numbers but suffer from several drawbacks: not having a population base (unselected consecutive patients), not being prospective, not having serial clinical data, and often having only transplant data (IBMTR, EBMT) which offer limited glimpse of the course of disease.

L2 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:824419 CAPLUS
DOCUMENT NUMBER: 137:304836
TITLE: Clinical application of hematopoietic factors
AUTHOR(S): Bessho, Masami
CORPORATE SOURCE: 1st Dep. Intern. Med., Saitama Med. Sch., Japan
SOURCE: Nippon Naika Gakkai Zasshi (2002),
91(Supplement, September), 229-235
CODEN: NNGAAS; ISSN: 0021-5384
PUBLISHER: Nippon Naika Gakkai
DOCUMENT TYPE: Journal; General Review
LANGUAGE: Japanese

AB A review on (1) biosynthesis, distribution, and functions of

erythropoietin (EPO) and its receptor, (2) clin. application of EPO in the treatment of anemia of chronic renal failure, (3) novel applications of EPO for the patients with cancers, myelodysplastic syndrome, or nervous system diseases, (4) clin. applications of G-CSF in patients with neutropenia, (5) possible involvement of G-CSF administration in the clonal complications in patients with aplastic anemia, (6) hematopoietic growth factors for platelet production, and (7) hematopoietic disorders induced by the antibodies to hematopoietic factors (EPO, thrombopoietin, etc.).

L2 ANSWER 4 OF 4 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 94295827 EMBASE

DOCUMENT NUMBER: 1994295827

TITLE: [The biological response modifiers. Current use and future in clinical practice].
LES MODIFICATEURS DE LA REPOSE BIOLOGIQUE. UTILISATION ACTUELLE ET AVENIR EN PRATIQUE LIBERALE.

AUTHOR: Kamioner D.

CORPORATE SOURCE: Dept. Hematologie/Oncologie Medicale, Centre Medico-Chirurgical, Rue Castiglione del Lago, 78190 Trappes, France

SOURCE: Bulletin de la Societe Francaise de Cancerologie Privee, (1994) Vol. 13, No. 37, pp. 64-69. .
ISSN: 0753-7417 CODEN: BFCPE5

COUNTRY: France

DOCUMENT TYPE: Journal; Conference Article

FILE SEGMENT: 016 Cancer
037 Drug Literature Index
038 Adverse Reactions Titles

LANGUAGE: French

SUMMARY LANGUAGE: English; French

ENTRY DATE: Entered STN: 2 Nov 1994

Last Updated on STN: 2 Nov 1994

AB The development of new cytokines or biological response modifiers allows great expectations in the treatment of various tumoral diseases such as renal carcinomas, malignant melanomas, acute leukemias or infectious diseases like viral hepatitis (Interferons, Interleukines), septic shock (Centoxin), but also in hematopoietic growth disorders (G-CSF, GM-CSF, erythropoietin). However the use of these drugs is restricted because of their high cost.

=> Log Off H

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 10:55:01 ON 18 JUL 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEGS1646

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *

SESSION RESUMED IN FILE 'MEDLINE, BIOSIS, CAPLUS, EMBASE'

AT 11:21:43 ON 18 JUL 2007

FILE 'MEDLINE' ENTERED AT 11:21:43 ON 18 JUL 2007

FILE 'BIOSIS' ENTERED AT 11:21:43 ON 18 JUL 2007
Copyright (c) 2007 The Thomson Corporation
FILE 'CAPLUS' ENTERED AT 11:21:43 ON 18 JUL 2007
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
FILE 'EMBASE' ENTERED AT 11:21:43 ON 18 JUL 2007
Copyright (c) 2007 Elsevier B.V. All rights reserved.

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	33.45	33.66
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.78	-0.78

=> D Hist

(FILE 'HOME' ENTERED AT 10:49:12 ON 18 JUL 2007)

FILE 'MEDLINE, BIOSIS, CAPLUS, EMBASE' ENTERED AT 10:49:38 ON 18 JUL 2007
L1 6 S G-CSF (L) (TREATM? OR THERAPY) (5A) (RENAL(2A) ((DISEASE OR FAIL
L2 4 DUP REM L1 (2 DUPLICATES REMOVED)

=> S CSF (L) (Treatm (3A)Nephropathy) AND pd<=20041014
2 FILES SEARCHED...
L3 0 CSF (L) (TREATMENT (3A) NEPHROPATHY) AND PD<=20041014

=> Log Off h

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 11:25:01 ON 18 JUL 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEGS1646

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	DEC 01	ChemPort single article sales feature unavailable
NEWS	3	FEB 02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS	4	FEB 02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS	5	FEB 06	Patent sequence location (PSL) data added to USGENE
NEWS	6	FEB 10	COMPENDEX reloaded and enhanced
NEWS	7	FEB 11	WTEXTILES reloaded and enhanced
NEWS	8	FEB 19	New patent-examiner citations in 300,000 CA/Caplus patent records provide insights into related prior art
NEWS	9	FEB 19	Increase the precision of your patent queries -- use terms from the IPC Thesaurus, Version 2009.01
NEWS	10	FEB 23	Several formats for image display and print options discontinued in USPATFULL and USPAT2
NEWS	11	FEB 23	MEDLINE now offers more precise author group fields

and 2009 MeSH terms

NEWS 12 FEB 23 TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms

NEWS 13 FEB 23 Three million new patent records blast AEROSPACE into STN patent clusters

NEWS 14 FEB 25 USGENE enhanced with patent family and legal status display data from INPADOCDB

NEWS 15 MAR 06 INPADOCDB and INPAFAMDB enhanced with new display formats

NEWS 16 MAR 11 EPFULL backfile enhanced with additional full-text applications and grants

NEWS 17 MAR 11 ESBIODBASE reloaded and enhanced

NEWS 18 MAR 20 CAS databases on STN enhanced with new super role for nanomaterial substances

NEWS 19 MAR 23 CA/CAPplus enhanced with more than 250,000 patent equivalents from China

NEWS 20 MAR 30 IMSPATENTS reloaded and enhanced

NEWS 21 APR 03 CAS coverage of exemplified prophetic substances enhanced

NEWS 22 APR 07 STN is raising the limits on saved answers

NEWS 23 APR 24 CA/CAPplus now has more comprehensive patent assignee information

NEWS 24 APR 26 USPATFULL and USPAT2 enhanced with patent assignment/reassignment information

NEWS 25 APR 28 CAS patent authority coverage expanded

NEWS 26 APR 28 ENCOMPLIT/ENCOMPLIT2 search fields enhanced

NEWS 27 APR 28 Limits doubled for structure searching in CAS REGISTRY

NEWS 28 MAY 08 STN Express, Version 8.4, now available

NEWS 29 MAY 11 STN on the Web enhanced

NEWS 30 MAY 11 BEILSTEIN substance information now available on STN Easy

NEWS 31 MAY 14 DGENE, PCTGEN and USGENE enhanced with increased limits for exact sequence match searches and introduction of free HIT display format

NEWS 32 MAY 15 INPADOCDB and INPAFAMDB enhanced with Chinese legal status data

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 10:38:38 ON 19 MAY 2009

=> File .Gerry2MBCE		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'MEDLINE' ENTERED AT 10:38:52 ON 19 MAY 2009

FILE 'BIOSIS' ENTERED AT 10:38:52 ON 19 MAY 2009

Copyright (c) 2009 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 10:38:52 ON 19 MAY 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 10:38:52 ON 19 MAY 2009

Copyright (c) 2009 Elsevier B.V. All rights reserved.

=> S ((Kataoka, M)/au OR (Yorozu, K)/au) AND G-CSF

L1 0 ((KATAOKA, M)/AU OR (YOROZU, K)/AU) AND G-CSF

=> S ((Kataoka, M)/au OR (Yorozu, K)/au) AND (Kidney OR Nephropathy)

L2 28 ((KATAOKA, M)/AU OR (YOROZU, K)/AU) AND (KIDNEY OR NEPHROPATHY)

=> Dup Rem L2

PROCESSING COMPLETED FOR L2

L3 22 DUP REM L2 (6 DUPLICATES REMOVED)

ANSWERS '1-12' FROM FILE MEDLINE

ANSWERS '13-15' FROM FILE BIOSIS

ANSWERS '16-18' FROM FILE CAPLUS

ANSWERS '19-22' FROM FILE EMBASE

=> D L3 Ti 1-22

L3 ANSWER 1 OF 22 MEDLINE on STN DUPLICATE 1

TI Effects of MRX-III on chronic renal failure in rats.

L3 ANSWER 2 OF 22 MEDLINE on STN DUPLICATE 2

TI Effects of total parenteral nutrition containing essential trace elements on their concentrations in rats.

L3 ANSWER 3 OF 22 MEDLINE on STN DUPLICATE 3

TI Changes in trace-element concentrations after intravenous injection of an essential trace-element preparation for parenteral use in rats.

L3 ANSWER 4 OF 22 MEDLINE on STN DUPLICATE 4

TI Supplementation of essential trace elements during total parenteral nutrition--effects on trace element-deficient rats.

L3 ANSWER 5 OF 22 MEDLINE on STN

TI Distribution of radiolabeled cis-diamminedichloroplatinum (II) on scintigraphic images in the tumor-bearing rabbit.

L3 ANSWER 6 OF 22 MEDLINE on STN

TI Treatment response on CT scan in patients with brain metastases treated with irradiation.

L3 ANSWER 7 OF 22 MEDLINE on STN

TI A microtiter method for long-term in vitro maintenance of human monocyte.

L3 ANSWER 8 OF 22 MEDLINE on STN

TI Effects of a new amino acids granule on rats with ischemic chronic renal failure (author's transl).

L3 ANSWER 9 OF 22 MEDLINE on STN

TI Studies of AMI-U-II, a new amino acids solution for renal failure. (III)

Effects of AMI-U-II on rabbits with ischemic chronic renal failure (author's transl).

- L3 ANSWER 10 OF 22 MEDLINE on STN
TI Studies of AMI-U-II, a new amino acids solution for renal failure. (II)
Effects of AMI-U-II on the incorporation of ¹⁵N (¹⁵N-urea) into serum albumin in the rabbit with ischemic acute renal failure (author's transl).
- L3 ANSWER 11 OF 22 MEDLINE on STN
TI Studies of AMI-U-H, a new amino acids solution for renal failure. (I)
Effects of AMI-U-II in rabbits with ischemic acute renal failure (author's transl).
- L3 ANSWER 12 OF 22 MEDLINE on STN
TI In vitro production of pyrrolidine from proline in the presence of rat brain tissue.
- L3 ANSWER 13 OF 22 BIOSIS COPYRIGHT (c) 2009 The Thomson Corporation on STN
DUPLICATE 5
TI STUDIES ON THE TRANSFER AND DISTRIBUTION OF CARBON-14 POLY CHLORINATED BI PHENYLS FROM MATERNAL TO FETAL AND SUCKLING RATS.
- L3 ANSWER 14 OF 22 BIOSIS COPYRIGHT (c) 2009 The Thomson Corporation on STN
TI ARSENIC DISTRIBUTION IN RATS ADMINISTERED ARSENIC-74 SUB CUTANEOUSLY AND EFFECTS OF ANTIDOTES AGAINST ARSENICAL ON THIS DISTRIBUTION.
- L3 ANSWER 15 OF 22 BIOSIS COPYRIGHT (c) 2009 The Thomson Corporation on STN
TI IN-VIVO PRODUCTION OF PIPERIDINE FROM PIPECOLIC-ACID IN THE RAT.
- L3 ANSWER 16 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN
TI Influence of Zn, Cu, Mn-mixture solution on metallothionein concentration and SOD activity of organ in rats fed Zn, Cu, Mn-deficient diet
- L3 ANSWER 17 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN
TI Experimental study on intralymphatic chemotherapy using ¹⁹⁵mPt-cis-diamminedichloroplatinum(II) with high specific activity
- L3 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN
TI Influence of an essential trace elements agent for parenteral use on metallothionein concentration in mice
- L3 ANSWER 19 OF 22 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN
TI Thermoradiotherapy combined with daily administration of low dose cisplatin for locally advanced laryngeal carcinoma.
- L3 ANSWER 20 OF 22 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN
TI Successful chemoradiotherapy for locally advanced gastric non-Hodgkin's lymphoma in a 3-year-2-month-old girl.
- L3 ANSWER 21 OF 22 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN
TI A new radioiodinated ligand for SPECT studies of peripheral benzodiazepine binding sites: 4'-Iodo-PK11195.
- L3 ANSWER 22 OF 22 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN
TI General pharmacological studies of MRX-III, a new amino acid solution for renal failure.

=> Log off H

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 10:42:59 ON 19 MAY 2009